IVIG for Immune Thrombocytopenia (ITP)
IVIG should be used in ITP when a rapid platelet rise is required—specifically, add IVIG 1 g/kg as a single dose to corticosteroids for patients with active bleeding, urgent surgery, or life-threatening hemorrhage; use IVIG alone (or with anti-D) only when corticosteroids are contraindicated. 1
First-Line Therapy: When to Add IVIG to Corticosteroids
Longer courses of corticosteroids are the preferred first-line treatment for newly diagnosed adult ITP with platelet counts <30 × 10⁹/L. 1 However, corticosteroids alone take days to achieve a platelet response, which may be unacceptable in certain clinical scenarios.
Add IVIG (1 g/kg single dose) to corticosteroids when:
- Active bleeding is present 1
- Urgent invasive procedures are planned 2, 3
- A more rapid platelet rise is required for any reason 1
IVIG has the most rapid onset of action among ITP therapies, typically raising platelets within 24 hours, compared to several days for corticosteroids. 2, 1 This makes IVIG the treatment of choice when speed is critical. The dose may be repeated if the initial response is inadequate. 1
IVIG may be discontinued after 1–2 days if an adequate platelet response is achieved, avoiding unnecessary exposure and cost. 2, 3
IVIG as Monotherapy: When Corticosteroids Are Contraindicated
Use IVIG alone (or anti-D in appropriate patients) as first-line therapy when corticosteroids are contraindicated. 1 This includes patients with:
- Uncontrolled diabetes
- Active infection
- Severe psychiatric disease
- Other absolute contraindications to corticosteroids 1
In these cases, IVIG 1 g/kg as a single dose is the recommended alternative. 1
Emergency Management: Life-Threatening Hemorrhage
For patients with life-, limb-, or sight-threatening bleeding (e.g., intracranial hemorrhage), combine IVIG with high-dose corticosteroids immediately. 1 IVIG is proven to have the most rapid onset of action in this setting. 1
Additional emergency measures include:
- Platelet transfusions (every 30 minutes to 8 hours), ideally with continuous IVIG infusion 1
- Recombinant factor VIIa (case reports show bleeding cessation, but thrombosis risk is significant—3 deaths in 18 reported cases) 1
- Emergent splenectomy (heroic measure; high surgical risk, lack of immunization, and bleeding during preparation) 1
Antifibrinolytic agents (aminocaproic acid, tranexamic acid) are discussed in case reports but have unproven efficacy. 1
Special Populations
Pregnancy
Pregnant patients requiring ITP treatment should receive corticosteroids or IVIG. 1, 3 IVIG is particularly useful when corticosteroids are poorly tolerated or contraindicated. 1
Secondary ITP
- HCV-associated ITP: If ITP treatment is required, IVIG is the preferred initial agent (corticosteroids may worsen viral replication). 1
- HIV-associated ITP: Treat HIV with antiretroviral therapy first; if ITP treatment is needed, use corticosteroids, IVIG, or anti-D. 1
Pediatric Patients
Observation is preferred over treatment for children with no or minor bleeding, regardless of platelet count. 4 When treatment is required, IVIG 0.8–1 g/kg as a single dose is an acceptable first-line option alongside short-course corticosteroids. 2, 3 Recent meta-analysis confirms that low-dose IVIG (≤1 g/kg) is as effective as high-dose IVIG (2 g/kg) in children, with fewer adverse reactions and lower cost. 5
IVIG Dosing and Administration
The recommended dose is 1 g/kg as a single infusion, repeatable if necessary. 1, 3 An alternative regimen is 0.4 g/kg/day for 1–2 days, which is equally effective but requires multiple infusions. 2, 3, 6
Infusion rate:
- Start at 0.01 mL/kg/min (0.5 mg/kg/min) 7
- Increase gradually to 0.10 mL/kg/min (5 mg/kg/min) if tolerated 7
- Monitor vital signs throughout; slow or stop if adverse reactions occur 7
High-risk patients (age ≥65, renal insufficiency, volume depletion, sepsis, nephrotoxic drugs):
Use the minimum effective dose and slowest feasible infusion rate, with close monitoring of renal function before and after infusion. 3, 7
Safety Considerations and Contraindications
Absolute contraindication:
IgA deficiency with anti-IgA antibodies and prior hypersensitivity to immunoglobulin. 3, 7 IVIG contains trace IgA and can cause anaphylaxis in these patients. 7
Black-box warnings:
- Thrombosis risk is increased in older, immobilized patients with hypercoagulable states, indwelling catheters, or cardiovascular risk factors. 3, 7
- Acute renal failure is a recognized risk, particularly with sucrose-containing formulations (FLEBOGAMMA 5% DIF does not contain sucrose). 7
Common adverse events:
Headache, flushing, fever, chills, fatigue, nausea, and blood pressure changes are the most frequently reported infusion-related reactions. 2, 3 Premedication with acetaminophen or corticosteroids reduces the incidence and severity of these reactions. 2, 3
When NOT to Use IVIG
Do not use IVIG as routine first-line monotherapy in stable, non-bleeding patients with newly diagnosed ITP. 1 Longer courses of corticosteroids are preferred because they are more cost-effective and provide sustained responses. 1
Do not combine rituximab with corticosteroids and IVIG as initial therapy—the 2019 ASH guidelines advise against this due to insufficient evidence of added benefit. 4, 3
Do not use IVIG for asymptomatic patients after splenectomy with platelet counts >30 × 10⁹/L. 1, 3
Key Pitfalls to Avoid
- Do not delay IVIG in life-threatening bleeding while waiting for corticosteroids to work—IVIG has the fastest onset of action. 1
- Do not use high-dose IVIG (2 g/kg) routinely in children—low-dose IVIG (≤1 g/kg) is equally effective with fewer adverse reactions and lower cost. 5
- Do not administer IVIG to patients with IgA deficiency and anti-IgA antibodies—this is an absolute contraindication. 3, 7
- Do not infuse IVIG rapidly in high-risk patients (elderly, renal insufficiency, volume depletion)—use the slowest feasible rate and monitor renal function. 3, 7